转化生长因子β诱导蛋白在胶质瘤中的表达及生物学功能

doi:10.3969/j.issn.1004-616x.2023.05.003

Abstract

Abstract: OBJECTIVE:To investigate expression and biological function of the transforming growth factor β-induced protein (TGFBI) in glioma. METHODS: The transcriptome data and the corresponding clinical information of tumor samples from glioma patients in the Cancer Genome Atlas (TCGA)、Chinese Glioma Genome Atlas (CGGA) and Rembrandt database were obtained to analyze potential associations between grades,subtypes, overall survival of glioma patients and TGFBI mRNA expression levels. Expression of TGFBI protein in 35 glioblastoma tissues and 5 normal brain tissues was analyzed using immunohistochemical method. Furthermore, the U87 and U373 cell lines were transfected with the constructed lentivirus vector containing shTGFBI target sequence to establish glioblastoma cell lines with low TGFBI expression and then to explore the effect of TGFBI on tumor proliferation、invasion、apoptosis and cell cycle. Finally,Gene set enrichment assay (GSEA) was used to predict the related pathways that TGFBI might participate in the occurrence and development of glioma. RESULTS: Results from TCGA、CGGA and Rembrandt databases showed that TGFBI expressions were positively correlated with the WHO grades (P<0.05). In addition,high expressions of TGFBI were correlated with inferior survival in glioma patients. Expressions of TGFBI in glioma tissues were significantly higher than that in normal brain tissues (P<0.05). The knockdown of TGFBI significantly inhibited proliferation and invasion of cancer cells、promoted cell apoptosis and promoted cell cycle progression from the G1 to the S phases. GSEA showed that high expressions of TGFBI were involved in activation of the TOLL-like receptors,NOD-like receptors and JAK-STAT signaling pathways. CONCLUSION: Overexpressions of TGFBI in gliomas promoted proliferation and invasion of tumor cells,inhibited cell apoptosis and induced cell cycle rearrangement. Thus,TGFBI might play an oncogene role in the occurrence and development of gliomas.

Key words: glioma, TGFBI, database, immunohistochemistry, prognosis judgment

CLC Number:

R739.4

GUO Wenjing, DENG Hui, SONG Ping, ZHANG Mengxian. Expression and biological functions of TGFBI in glioma[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(5): 341-348.

References

[1] WANG Z Y, SU G H, DAI Z Y, et al. Circadian clock genes promote glioma progression by affecting tumour immune infiltration and tumour cell proliferation[J]. Cell Prolif, 2021, 54(3):e12988.
[2] OSTROM Q T, BAUCHET L, DAVIS F G, et al. The epidemiology of glioma in adults:a "state of the science" review[J]. Neuro Oncol, 2014, 16(7):896-913.
[3] CORONA A, BLOBE G C. The role of the extracellular matrix protein TGFBI in cancer[J]. Cell Signal, 2021, 84:110028.
[4] HAN B, CAI H L, CHEN Y, et al. The role of TGFBI in gastrointestinal tract tumorigenesis[J]. Mol Cancer, 2015, 14:64.
[5] BHAGIRATH D, ABROL N, KHAN R, et al. Expression of CD147, BIGH3 and Stathmin and their potential role as diagnostic marker in patients with urothelial carcinoma of the bladder[J]. Clin Chim Acta, 2012, 413(19/20):1641-1646.
[6] OZAWA D, YOKOBORI T, SOHDA M, et al. TGFBI expression in cancer stromal cells is associated with poor prognosis and hematogenous recurrence in esophageal squamous cell carcinoma[J]. Ann Surg Oncol, 2016, 23(1):282-289.
[7] WEN G Y, PARTRIDGE M A, LI B Y, et al. TGFBI expression reduces in vitro and in vivo metastatic potential of lung and breast tumor cells[J]. Cancer Lett, 2011, 308(1):23-32.
[8] LI B Y, WEN G Y, ZHAO Y L, et al. The role of TGFBI in mesothelioma and breast cancer:association with tumor suppression[J]. BMC Cancer, 2012, 12:239.
[9] LAPOINTE S, PERRY A, BUTOWSKI N A. Primary brain tumours in adults[J]. Lancet, 2018, 392(10145):432-446.
[10] TORRE L A, BRAY F, SIEGEL R L, et al. Global cancer statistics, 2012[J]. CA, 2015, 65(2):87-108.
[11] MASSAGUÉ J. TGFβ signalling in context[J]. Nat Rev Mol Cell Biol, 2012, 13(10):616-630.
[12] WEEN M P, OEHLER M K, RICCIARDELLI C. Transforming growth factor-beta-induced protein (TGFBI):a matrix protein with dual functions in ovarian cancer[J]. Int J Mol Sci, 2012, 13(8):10461-10477.
[13] YOKOBORI T, NISHIYAMA M. TGF-β signaling in gastrointestinal cancers:progress in basic and clinical research[J]. J Clin Med, 2017, 6(1):11.
[14] KARLAN B Y, DERING J, WALSH C, et al. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer[J]. Gynecol Oncol, 2014, 132(2):334-342.
[15] LEBDAI S, VERHOEST G, PARIKH H, et al. Identification and validation of TGFBI as a promising prognosis marker of clear cell renal cell carcinoma[J]. Urol Oncol, 2015, 33(2):69. e11-69.e18.
[16] LAUDEN L, SIEWIERA J, BOUKOUACI W, et al. TGF-β-induced (TGFBI) protein in melanoma:a signature of high metastatic potential[J]. J Invest Dermatol, 2014, 134(6):1675-1685.
[17] ZHU J, CHEN X J, LIAO Z C, et al. TGFBI protein high expression predicts poor prognosis in colorectal cancer patients[J]. Int J Clin Exp Pathol, 2015, 8(1):702-710.
[18] SEOK Y, LEE W K, PARK J Y, et al. TGFBI promoter methylation is associated with poor prognosis in lung adenocarcinoma patients[J]. Mol Cells, 2019, 42(2):161-165.
[19] FANG H B, LIU J, GUO D, et al. Epigenetic regulation of putative tumor suppressor TGFBI in human leukemias[J]. Chin Med J, 2014, 127(9):1645-1650.
[20] GUO S K, SHEN M F, YAO H W, et al. Enhanced expression of TGFBI promotes the proliferation and migration of glioma cells[J]. Cell Physiol Biochem, 2018, 49(3):1097-1109.
[21] 朱洪涛, 刘丹, 陈籽荣, 等. 肿瘤相关巨噬细胞分泌转化生长因子-β诱导蛋白影响胶质瘤干细胞特性的体外研究[J]. 中国现代神经疾病杂志, 2019, 19(12):936-944.
[22] LI L, ACIOGLU C, HEARY R F, et al. Role of astroglial toll-like receptors (TLRs) in central nervous system infections, injury and neurodegenerative diseases[J]. Brain Behav Immun, 2021, 91:740-755.
[23] URBAN-WOJCIUK Z, KHAN M M, OYLER B L, et al. The role of TLRs in anti-cancer immunity and tumor rejection[J]. Front Immunol, 2019, 10:2388.
[24] HUANG Y M, ZHANG Q, LUBAS M, et al. Synergistic toll-like receptor 3/9 signaling affects properties and impairs glioma-promoting activity of microglia[J]. J Neurosci, 2020, 40(33):6428-6443.
[25] LIU P, LU Z W, LIU L L, et al. NOD-like receptor signaling in inflammation-associated cancers:from functions to targeted therapies[J]. Phytomedicine, 2019, 64:152925.
[26] SAXENA S, JHA S. Role of NOD-like Receptors in Glioma Angiogenesis:insights into future therapeutic interventions[J]. Cytokine Growth Factor Rev, 2017, 34:15-26.
[27] XUE L P, LU B, GAO B B, et al. NLRP3 promotes glioma cell proliferation and invasion via the interleukin-1β/NF-κB p65 signals[J]. Oncol Res, 2019, 27(5):557-564.
[28] OWEN K L, BROCKWELL N K, PARKER B S. JAK-STAT signaling:a double-edged sword of immune regulation and cancer progression[J]. Cancers, 2019, 11(12):2002.
[29] HENRIK H D, RAVI V M, BEHRINGER S P, et al. Tumorassociated reactive astrocytes aid the evolution of immunosuppressive environment in glioblastoma[J]. Nat Commun, 2019, 10(1):2541.

Expression and biological functions of TGFBI in glioma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	MENG Lin, YANG Huayu, MA Xiumei. Expression of the splicing factor SF2/ASF in pancreatic cancer tissues and its relationship with clinicopathological features [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(3): 209-214.
[2]	HUANG Lidan, WU Yueming, WANG Yadi, TAN Qi. Relationships between VEGF-A protein expression and EGFR mutation in patients with lung adenocarcinomas and its clinical significance [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(2): 116-120.
[3]	YU Yunliang, WANG Lili, LI Ting, FENG Jiankai. Correlations among P2RX1,prognosis and immune cells infiltration in lung adenocarcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(5): 353-360,365.
[4]	JIAO Wenjing, ZHANG Jinyan, MA Ming, GUO Xiujuan, FENG Junhua, SHAO Junguo, JIAO Wenpeng. Expression and clinical significance of MTDH and FoxM1 in hepatocellular carcinomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(5): 349-353,359.
[5]	ZHENG Jiantao, YANG Yong, ZHOU Dong. Clinical significance of CX43 expression and immune cell infiltration in glioma: based on TCGA data analyses [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 250-254,261.
[6]	ZHANG Shimin, ZHAO Ruijun. Expression of protein tyrosine phosphatase receptor J in breast cancer tissues and its relationship with clinical prognosis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 276-279,285.
[7]	WANG Yaokun, CHEN Juexiao, ZHANG Mingyuan, SHAO Changli, YANG Yu, SHANG Yu. Database analysis of genome variations and targeted drug screening of anaplastic thyroid cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(1): 53-57.
[8]	DU Qiang, YAO Yiyong, ZENG Gang. Expression and clinical significance of ASPM in lung adenocarcinoma according to the TCGA database [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 457-463.
[9]	YANG Xiuyuan, PAN Yuelong. Expression of CD10 protein in colorectal carcinomas and its clinical significance [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(5): 344-349.
[10]	TAO Yan, LI Lanlan, LU Jianzhong, LIU Shanhui, FU Shengjun, ZHANG Jing. Expression and clinical significance of FOXO3 gene in bladder cancer based on bioinformatics database [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(5): 374-379.
[11]	WAN Xin, HU Yue, ZHANG Ju, CHEN Yun, JIN Peipei. Human herpesvirus 6A subtype affects the expression of LncRNA MEG3,proliferation,apoptosis and EMT process in glioma cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(5): 352-358.
[12]	GAO Jie, ZHANG Xiao, WEI Chao. Involvement of differentially expressed miRNA in prognosis of pancreatic cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(3): 173-179.
[13]	DONG Qiang, XIE Qiqi, HU Jianhong, WANG Maolin, YUAN Guoqiang, PAN Yawen. Bioinformatic analysis of expression and clinical significance of formyl peptide receptor 1 in gliomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(6): 457-462.
[14]	LIU Ying, WANG Ke, HE Yangting, XIAO Jinrong, WANG Huanzhuo, LI Yangkai, WEI Sheng. Prognosis-associated lncRNA signature in lung squamous cell carcinomas based on TCGA database [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(6): 468-472,478.
[15]	HUANG Zhuangcheng, WANG Honghao, SHEN Peilin, LIN Ming'en, HE Xuejun. Expression and clinical significance of Notch signalingrelated proteins in cystitis glandularis and bladder cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(5): 374-377,383.